Home/Pipeline/CDMO - Client Molecule A

CDMO - Client Molecule A

Oncology

Phase IIIActiveConfidential

Key Facts

Indication

Oncology

Phase

Phase III

Status

Active

Company

Gland Pharma

About Gland Pharma

Gland Pharma's mission is to be a leading global provider of high-quality, affordable injectable medicines. The company has achieved this through a combination of deep expertise in complex sterile manufacturing, strategic partnerships like the one with Fosun Pharma, and a successful IPO in 2020. Its core strategy focuses on expanding its CDMO business, leveraging its R&D for differentiated formulations, and penetrating new regulated and emerging markets to drive sustainable growth.

View full company profile

Therapeutic Areas

Anti-infectives Cardiology Critical Care Oncology Nephrology Anesthesia

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active